



Contact:  
Louis Herlands, Ph.D. - Chairman and CEO  
[LHerlands@LuminousMindInc.com](mailto:LHerlands@LuminousMindInc.com)  
P: 800-816-9630 x702  
Cambridge, MA

## **Luminous Mind, Inc. Announces the Publication of an International Patent Application for Non-Hallucinogenic Psychedelic Fungi**

*This patent application for Non-Hallucinogenic Psychedelic Fungi is crucial, in that it is not limited to nutraceuticals but potentially can be extended to become a valuable fungal synthetic biology platform used to create impactful new pharmaceuticals for Central Nervous System (CNS) disorders.*

**Boston – March 26, 2024.** Luminous Mind, Inc. (LMI) announces the publication of an international Patent Cooperation Treaty (PCT) patent application which relates to non-hallucinogenic psychedelic fungi, and methods of their use, including as functional foods, nootropics, legal microdoses, nutraceuticals, and therapeutics. The application, published as WO2024/035954, has a priority date of August 11, 2022 representing LMI's early ground-breaking work in the field, and enables patent rights to be pursued in all of the 157 PCT contracting states. LMI estimates that the global market for these innovative, psilocybin-depleted mushroom extracts could exceed \$1 billion in the next five years. This projection is grounded in a deep understanding of market dynamics and a strong belief in this cutting-edge technology.

Louis Herlands, Ph.D., CEO of LMI, said "A key point is what we propose is novel, beneficial, functional and highly important - even surprising - as most companies are striving to increase psilocybin production, we take it out to maximize the useful compounds remaining. I am thrilled to discuss the transformative impact of our latest patent application in the field of psilocybin mushroom research. This patent application is not just an achievement; it's a pivotal moment that will spearhead the potential development of numerous novel nutraceutical products and new medicines. We're leveraging CRISPR technology to maintain a host of beneficial molecules in these mushrooms while completely removing psilocybin."

**For more detailed information on our patent application, please click on this link to review our [COMMENTARY: "When it comes to magic mushrooms, less is more."](#)**



**Psilocybe Cubensis Mushrooms**

Psilocybin-producing fungi, commonly known as "magic mushrooms," are a polyphyletic group of fungi that enzymatically synthesize and thus contain psilocybin which, upon ingestion, is rapidly converted to its metabolite psilocin which is the compound responsible for the "psychedelic" effects of magic mushrooms.

This invention provides gene-edited fungi, such as non-hallucinogenic psychedelic fungi, in which a biochemical pathway to produce a bioactive alkaloid is disrupted. In some aspects, the psilocybin biosynthesis pathway is disrupted, resulting in non-hallucinogenic psychedelic fungi which do not produce or contain psilocybin, or which produce or contain a substantially reduced amount of psilocybin relative to wild-type fungi.

Myles Axton, Ph.D., Chief Genetics Researcher of LMI, said "I am most excited that this genetic innovation will let mushrooms produce useful levels of over a dozen amazing compounds that would be present only in tiny amounts in a psychedelic mushroom and which we might otherwise obtain only under the most restricted lab conditions. I think what we propose could be the foundation for a platform for synthetic biology based on fungal genomics."

By capitalizing on this key innovation, LMI aims to redefine the health and wellness landscape, providing consumers with groundbreaking, effective, and non-psychoactive options. LMI is not just adapting to industry trends—we're setting them, ensuring our market leadership and fulfilling our commitment to deliver exceptional wellness products.

About Luminous Mind Inc.

Luminous Mind Inc., with its focus on Central Nervous System (CNS) disorders, such as anxiety, depression, chronic pain, PTSD, anorexia and schizophrenia, applies a rigorous therapeutic discovery and development process that includes the repurposing of existing, abandoned, and developmental compounds for new indications. Groundbreaking scientific insights in neuroscience, genetics, systems biology, and brain circuitry, together with powerful new tools drive its discovery efforts. For additional information, please visit [www.LuminousMindInc.com](http://www.LuminousMindInc.com).